The brief

Analyst view

• TEMPO platform enables epigenome editing: alters gene expression without cutting DNA.
• TUNE-401 for hepatitis B showed positive Phase 1b/2a data in May 2026.
• Raised $175M Series B in January 2025 to advance clinical development.

Technical approach

As reported

TEMPO Platform

Epigenome editing without DNA cutting

Changes chemical tags that control gene activity, leaving DNA unchanged. Enables precise activation, silencing, or fine-tuning of genes.

LNP Delivery

Lipid nanoparticle delivery to target cells

TUNE-401 is delivered intravenously as an LNP-RNA therapy that translates in the liver into a protein that silences hepatitis B virus DNA.

Broad Application

Applicable to many chronic diseases

Targets age-related diseases, inflammation, and dysregulated genes in late-onset conditions.